L(-)-塔洛糖 | 23567-25-1

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: L(-)-塔洛糖
• 中文别名: L-(-)-塔洛糖；L-(-)-塔罗糖
• 英文名称: L-talose
• 英文别名: (2R,3R,4R,5S)-2,3,4,5,6-pentahydroxyhexanal
• CAS: 23567-25-1
• 化学式: C₆H₁₂O₆
• 分子量: 180.158
• InChiKey: GZCGUPFRVQAUEE-OMMKOOBNSA-N

物化性质

• 熔点：
  120-123 °C
• 沸点：
  232.96°C (rough estimate)
• 密度：
  1.2805 (rough estimate)
• 溶解度：
  DMSO（少许）、水（少许）
• 稳定性/保质期：
  在常温常压下稳定，应避免接触强氧化剂。

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  118
• 氢给体数：
  5
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2912491000
• 储存条件：
  将物品存放在密封的容器中，并置于阴凉、干燥处保存。

SDS

Name:	L-(-)-Talose 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	23567-25-1

Section 1 - Chemical Product MSDS Name:L-(-)-Talose 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
23567-25-1	L-(-)-Talose	98%	245-744-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 23567-25-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 120.00 - 123.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H12O6
Molecular Weight: 180.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 23567-25-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
L-(-)-Talose - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 23567-25-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 23567-25-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 23567-25-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

作用机制

L-塔罗糖是人体内重要的糖分子，参与碳水化合物、蛋白质和脂类的代谢。它是一种己糖，含有六个碳原子，并由己糖激酶催化磷酸化。磷酸化的L-塔罗糖随后被转化为果糖-6-磷酸，进一步转化为葡萄糖-6-磷酸。最终，葡萄糖-6-磷酸用于糖酵解、柠檬酸循环和其他代谢途径。

作用

L(-)-塔洛糖是一种己糖，在人体中扮演着重要作用，尤其是在碳水化合物、蛋白质和脂类的代谢过程中。它在多种生理功能中发挥关键作用。

应用

L(-)-塔罗糖具有广泛的研究应用价值。它用于合成低聚糖，这些低聚糖进一步应用于糖蛋白和糖脂的研究。此外，L(-)-塔罗糖还被用来合成糖基化化合物，从而帮助研究碳水化合物代谢及糖蛋白的结构与功能。同时，它还可用于合成糖基化药物，以治疗各种疾病。

反应信息

• 作为反应物：
  描述：

  L(-)-塔洛糖 在 5’-三磷酸腺苷 作用下， 生成 Fructose-1-phosphat
  参考文献：
  名称：

  Enzymatic syntheses of rare ketose 1-phosphates

  摘要：

  Ketose 1-phosphates are obtained from aldehydes and dihydroxyacetone phosphate by enzymatic aldol addition, and from aldoses (or ketoses) by isomerization/phosphorylation. The microbial enzymes employed are readily available by overexpression.

  DOI：

  10.1016/s0040-4039(00)79140-4
• 作为产物：
  描述：

  在 palladium dihydroxide 氢气 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 L(-)-塔洛糖
  参考文献：
  名称：

  从常见的手性结构单元到醛糖己糖的新的聚合路线。

  摘要：

  [文本中的反应]从常见的环己酸手性结构单元开始，开发了一种非对映控制的途径来合成8个醛己糖。

  DOI：

  10.1021/ol015733i

文献信息

• A carbohydrate synthesis employing a photochemical decarbonylation
  作者：Kohei Kadota、Kunio Ogasawara

  DOI：10.1016/s0040-4039(01)01874-3

  日期：2001.12

  to the aldopentoses, ribose and lyxose, and the aldohexoses, talose and gulose, has been developed using chiral building blocks containing a bicyclo[3.2.1]octane framework by employing a photochemical decarbonylation reaction as the key step.

  利用光化学脱羰反应作为关键步骤，使用含有双环[3.2.1]辛烷骨架的手性结构单元，已经开发了一条通往醛糖，核糖和lyxose，醛己糖，talose和gulose的新途径。
• Strong Metal Phosphide–Phosphate Support Interaction for Enhanced Non‐Noble Metal Catalysis
  作者：Zemin Chen、Xiang Zeng、Xinyu Li、Zhenxing Lv、Jiong Li、Ying Zhang

  DOI：10.1002/adma.202106724

  日期：2022.2

  the NPs. The encapsulation state of metal phosphide and charge transfer are identical to those of classical SMSIs and can be optimally regulated. Furthermore, the strong interactions of Co2PL/MnP-3 not only significantly enhance the anti-oxidation and anti-acid capability of non-noble metal but also exhibit excellent catalytic activity and stability toward hydrogenating a wide range of compounds into

  强金属-载体相互作用（SMSI）对于多相催化中的负载型催化剂至关重要。这是关于强金属磷化物-磷酸盐载体相互作用（SMPSI）的第一份报告。SMPSI 的关键是载体上 P 物质的活化，这导致同时生成金属磷化物纳米粒子 (NPs) 和由载体迁移到 NPs 上形成的核壳纳米结构。金属磷化物的封装状态和电荷转移与经典 SMSIs 相同，可以进行最佳调节。此外，Co 2 P L的强相互作用/MnP-3不仅显着提高了非贵金属的抗氧化和抗酸能力，而且对多种化合物加氢成高附加值精细化学品表现出优异的催化活性和稳定性，100%选择性，是甚至优于 Pd/C 和 Pt/C。SMPSI结构一般可以扩展到其他体系，例如Ni 2 P L /Mn 3 (PO 4 ) 2、Co 2 P L /LaPO 4和CoP L /CePO 4. 该研究为先进的非贵金属催化剂的合理设计提供了一种新方法，并为纳米颗粒与载体之间的强相互作用引入了一种新的范式。
• Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
  申请人：ENGENE, INC.

  公开号：US10456481B2

  公开（公告）日：2019-10-29

  Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

  本文提供了壳聚糖衍生物纳米粒子，包括用阳离子氨基酸和亲水多元醇官能化的壳聚糖；以及制造和使用这种纳米粒子的方法，例如用于体内基因递送。
• Diagnosis and treatment of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：US10514383B2

  公开（公告）日：2019-12-24

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

  代谢物和代谢物特征（组）可作为生物标记物用于临床诊断，尤其是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经系统结果，还可用于诊断疾病进展和治疗效果。本研究提供了一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区、脑损伤风险以及由于确定不同脑组织（特别是海马和/或基底节）的损伤类型和程度而导致的预后和神经系统结局。
• Total synthesis of the L-hexoses
  作者：Soo Y. Ko、Albert W.M. Lee、Satoru Masamune、Lawrence A. Reed、K. Barry Sharpless、Frederick J. Walker

  DOI：10.1016/s0040-4020(01)97596-9

  日期：1990.1